US5679399A
(en)
|
1987-07-17 |
1997-10-21 |
Bio Barrier, Inc. |
Method of forming a membrane, especially a latex or polymer membrane, including multiple discrete layers
|
US5549924A
(en)
*
|
1987-07-17 |
1996-08-27 |
Robin Renee Thill Shlenker |
Method of forming a membrane, especially a latex or polymer membrane, including a deactivating barrier and indicating layer
|
JPH01153633A
(ja)
*
|
1987-12-10 |
1989-06-15 |
Kyorin Pharmaceut Co Ltd |
経皮吸収製剤
|
US5633009A
(en)
*
|
1990-11-28 |
1997-05-27 |
Sano Corporation |
Transdermal administration of azapirones
|
US5613958A
(en)
*
|
1993-05-12 |
1997-03-25 |
Pp Holdings Inc. |
Transdermal delivery systems for the modulated administration of drugs
|
US20050152950A1
(en)
*
|
1995-11-13 |
2005-07-14 |
Saffran Bruce N. |
Method and apparatus for macromolecular delivery using a coated membrane
|
US5708036A
(en)
*
|
1996-01-29 |
1998-01-13 |
Pesterfield, Jr.; E. Charles |
Method of treating premature uterine contractions using the optically active R(-)-isomer of albuterol
|
CA2247953A1
(en)
*
|
1996-01-29 |
1997-07-31 |
E. Charles Pesterfield Jr. |
Method of treating undesired uterine contractions using optically pure r- or rr-isomers of adrenergic beta-2 agonists
|
US5837289A
(en)
*
|
1996-07-23 |
1998-11-17 |
Grasela; John C. |
Transdermal delivery of medications using a combination of penetration enhancers
|
US6248789B1
(en)
|
1996-08-29 |
2001-06-19 |
Stuart L. Weg |
Administration of ketamine to manage pain and to reduce drug dependency
|
GB9719076D0
(en)
*
|
1997-09-09 |
1997-11-12 |
Movevirgo Limited |
A material for producing a medical dressing and a medical dressing produced using the material
|
CN100357143C
(zh)
*
|
1998-01-20 |
2007-12-26 |
易通公司 |
起步发动机扭矩限制
|
US5900249A
(en)
*
|
1998-02-09 |
1999-05-04 |
Smith; David J. |
Multicomponent pain relief topical medication
|
SE9803240D0
(sv)
*
|
1998-09-24 |
1998-09-24 |
Diabact Ab |
A pharmaceutical composition having a rapid action
|
KR100369779B1
(ko)
*
|
1999-07-12 |
2003-01-29 |
주식회사 엘지생명과학 |
교감신경 흥분성 기관지확장 약물의 경피흡수 투여용 조성물및 이를 포함하는 경피흡수 투여용 제형
|
US7713546B1
(en)
*
|
2001-04-03 |
2010-05-11 |
Soft Gel Technologies, Inc. |
Corosolic acid formulation and its application for weight-loss management and blood sugar balance
|
US20070218087A1
(en)
*
|
2001-12-07 |
2007-09-20 |
Norbert Hoenzelaer |
Method of controlled release of vanillin for nasal and/or pulmonary uptake
|
DE10200578A1
(de)
*
|
2002-01-09 |
2003-07-10 |
Roehm Gmbh |
Haft- und Bindemittel für dermale oder transdermale Therapiesysteme
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
EP1546184A4
(en)
*
|
2002-07-16 |
2006-08-23 |
Univ South Florida |
HUMAN IMMUNOSUPPRESSIVE PROTEIN
|
EP2316459B1
(en)
|
2002-07-29 |
2013-11-06 |
Rigel Pharmaceuticals, Inc. |
2,4-pyrimidinediamine compounds for use in methods of treating or preventing autoimmune diseases
|
US7241456B2
(en)
*
|
2002-10-25 |
2007-07-10 |
Australian Importers Ltd. |
Formulations for topical delivery of bioactive substances and methods for their use
|
ATE432697T1
(de)
|
2002-11-18 |
2009-06-15 |
Yaupon Therapeutics Inc |
Analgetische verwendung von (s)-norketamin
|
WO2004075075A1
(en)
*
|
2003-01-21 |
2004-09-02 |
Alza Corporation |
A computational model for transdermal drug delivery
|
US20060246104A1
(en)
*
|
2003-04-16 |
2006-11-02 |
Massia Stephen P |
Stable rgd peptidomimetic composition
|
DK1663242T3
(da)
|
2003-08-07 |
2011-08-01 |
Rigel Pharmaceuticals Inc |
2,4-Pyrimidindiamin-forbindelser og anvendelse som antiproliferative midler
|
US20050186269A1
(en)
*
|
2004-02-25 |
2005-08-25 |
Udell Ronald G. |
Stabilized feverfew formulations
|
US8168600B2
(en)
*
|
2004-04-23 |
2012-05-01 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for topical delivery of oligonucleotides
|
US20060051435A1
(en)
*
|
2004-08-19 |
2006-03-09 |
Udell Ronald G |
Nutritional supplement for body fat reduction
|
US9050393B2
(en)
|
2005-02-08 |
2015-06-09 |
Bruce N. Saffran |
Medical devices and methods for modulation of physiology using device-based surface chemistry
|
US20070104805A1
(en)
*
|
2005-11-01 |
2007-05-10 |
Udell Ronald G |
Compositions of Hoodia Gordonii and Pinolenic Acid Derivatives
|
AT502717A1
(de)
*
|
2005-11-09 |
2007-05-15 |
Omnica Gmbh |
Pharmazeutische verwendung einer verbindung
|
GB0523031D0
(en)
*
|
2005-11-11 |
2005-12-21 |
Yaupon Therapeutics |
Enhancement of morphine analgesia by s(-)-norketamine
|
ES2622493T3
(es)
|
2006-02-24 |
2017-07-06 |
Rigel Pharmaceuticals, Inc. |
Composiciones y métodos para la inhibición de la ruta de JAK
|
US9109204B2
(en)
*
|
2006-02-28 |
2015-08-18 |
The Trustees Of Columbia University In The City Of New York |
Methods for compact aggregation of dermal cells
|
AT503329A1
(de)
*
|
2006-03-02 |
2007-09-15 |
Omnica Gmbh |
Verfahren zur herstellung einer zusammensetzung, welche zumindest ein xantophyll enthält
|
AT503521A1
(de)
*
|
2006-05-05 |
2007-11-15 |
Omnica Gmbh |
Verwendung eines extraktes von kiwi-frucht
|
US8278358B2
(en)
*
|
2006-07-06 |
2012-10-02 |
Omnica Gmbh |
Lipoic acid derivatives
|
JP2008044926A
(ja)
*
|
2006-08-14 |
2008-02-28 |
Trustees Of Columbia Univ In The City Of New York |
Wnt信号伝達に関係した分泌タンパク質
|
CA2673125C
(en)
|
2006-10-19 |
2015-04-21 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
US8163902B2
(en)
|
2006-11-21 |
2012-04-24 |
Rigel Pharmaceuticals, Inc. |
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
|
US7820207B2
(en)
|
2007-03-15 |
2010-10-26 |
Omnica Gmbh |
Stabilized anthocyanin compositions
|
US8623429B2
(en)
|
2007-03-15 |
2014-01-07 |
Omnica Gmbh |
Stabilized anthocyanin compositions
|
CA2835910C
(en)
*
|
2007-04-25 |
2016-06-28 |
Warner Chilcott Company, Llc |
Improved vitamin d content uniformity in pharmaceutical dosage forms
|
US20080293644A1
(en)
*
|
2007-04-27 |
2008-11-27 |
Thomas Eidenberger |
Guava extract
|
US8034983B2
(en)
*
|
2007-06-06 |
2011-10-11 |
Multi-Tech Specialty Chemicals, Co., Ltd. |
Process for the preparation of xanthophyll crystals
|
EP2234608A2
(en)
|
2007-12-11 |
2010-10-06 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
|
WO2009089380A2
(en)
*
|
2008-01-08 |
2009-07-16 |
The Trustees Of Columbia University In The City Of New York |
Methods for p2ry5 mediated regulation of hair growth and mutants thereof
|
US20090264433A1
(en)
*
|
2008-04-21 |
2009-10-22 |
Institute For Oneworld Health |
Compounds, Compositions and Methods Comprising Triazine Derivatives
|
WO2009131951A2
(en)
*
|
2008-04-21 |
2009-10-29 |
Institute For Oneworld Health |
Compounds, compositions and methods comprising isoxazole derivatives
|
EP2278879B1
(en)
*
|
2008-04-21 |
2016-06-15 |
PATH Drug Solutions |
Compounds, compositions and methods comprising oxadiazole derivatives
|
US20090270398A1
(en)
*
|
2008-04-21 |
2009-10-29 |
Institute For Oneworld Health |
Compounds, Compositions and Methods Comprising Pyridazine Derivatives
|
SI2367812T1
(sl)
*
|
2008-08-22 |
2016-01-29 |
Sanofi |
(4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(7-fluoro-1-(2-metoksi- etil)-4trifluorometoksi-1H-indol-3-il)metanon kot inhibitor mastocitne triptaze
|
US20110237528A1
(en)
*
|
2008-09-19 |
2011-09-29 |
Institute For Oneworld Health |
Compositions and methods comprising imidazole and triazole derivatives
|
TW201034675A
(en)
|
2008-12-18 |
2010-10-01 |
Sanofi Aventis |
Method for treating macular degeneration
|
EP2382210B1
(en)
|
2008-12-30 |
2017-03-01 |
Rigel Pharmaceuticals, Inc. |
Pyrimidinediamine kinase inhibitors
|
DK2389372T3
(en)
|
2009-01-23 |
2015-12-14 |
Rigel Pharmaceuticals Inc |
COMPOSITIONS AND METHODS FOR INHIBITION OF JAK pathway
|
CN104523661A
(zh)
|
2009-02-06 |
2015-04-22 |
南加利福尼亚大学 |
含有单萜的治疗组合物
|
US8511216B2
(en)
*
|
2009-03-30 |
2013-08-20 |
Kanzaki Kokyukoki Mfg. Co., Ltd. |
Hydraulic actuator unit
|
US8343976B2
(en)
*
|
2009-04-20 |
2013-01-01 |
Institute For Oneworld Health |
Compounds, compositions and methods comprising pyrazole derivatives
|
MX2012000435A
(es)
|
2009-07-08 |
2012-06-01 |
Dermira Canada Inc |
Analogos de acido 5-(tetradeciloxi)-2-furancarboxilico (tofa) utiles en el tratamiento de trastornos o afecciones dermatologicas.
|
US20110034415A1
(en)
|
2009-07-20 |
2011-02-10 |
Thomas Eidenberger |
Walnut extracts for nutraceutical applications
|
FR2955324A1
(fr)
|
2010-01-15 |
2011-07-22 |
Sanofi Aventis |
[4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones disubstituees
|
US20110144200A1
(en)
|
2009-12-14 |
2011-06-16 |
Thomas Eidenberger |
Combination of carotenoids and epi-lutein
|
WO2011078984A1
(en)
|
2009-12-23 |
2011-06-30 |
Sanofi |
[4[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1h-pyrrolo-pyridin-yl)-methanones and synthesis thereof
|
PT2516418E
(pt)
|
2009-12-23 |
2014-07-18 |
Sanofi Sa |
Profármacos de [4[4-(5-aminometil-2-fluoro-fenil)-piperidin-1- il]-(1h-pirrolo-piridin-il)-metanonas e sua síntese
|
WO2011130716A2
(en)
|
2010-04-16 |
2011-10-20 |
Access Pharmaceuticals, Inc. |
A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers
|
WO2011133596A1
(en)
|
2010-04-20 |
2011-10-27 |
Institute For Oneworld Health |
Compounds, compositions and methods comprising 1,3,4-oxadiazole derivatives
|
EP2560654A1
(en)
|
2010-04-20 |
2013-02-27 |
Institute for OneWorld Health |
Compounds, compositions and methods comprising pyridazine sulfonamide derivatives
|
ES2563319T3
(es)
|
2010-04-24 |
2016-03-14 |
Viamet Pharmaceuticals, Inc. |
Compuestos inhibidores de metaloenzimas
|
US20120208855A1
(en)
|
2010-07-12 |
2012-08-16 |
Sanofi |
Amino-benzoic acid derivatives for use in the treatment of dihydrogenase-related disorders
|
BR112013001632B1
(pt)
|
2010-07-28 |
2021-05-25 |
Rigel Pharmaceuticals |
composto, composição farmacêutica, e, método de fabricar um composto
|
US8968755B2
(en)
|
2010-10-23 |
2015-03-03 |
Joel Schlessinger |
Topical base and active agent-containing compositions, and methods for improving and treating skin
|
US8685381B2
(en)
|
2010-10-23 |
2014-04-01 |
Joel Schlessinger |
Topical base and active agent-containing compositions, and methods for improving and treating skin
|
US9056855B2
(en)
|
2010-10-28 |
2015-06-16 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitor compounds
|
WO2013149194A1
(en)
|
2012-03-29 |
2013-10-03 |
The Trustees Of Columbia University In The City Of New York |
Methods for treating hair loss disorders
|
KR101913293B1
(ko)
|
2010-11-02 |
2018-10-30 |
더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 |
탈모 질환의 치료 방법
|
ES2703498T3
(es)
|
2010-11-13 |
2019-03-11 |
Innocrin Pharmaceuticals Inc |
1-(6,7-Bis(difluorometoxi)naftalen-2-il)-2-metil-1-(1H-1,2,3-triazol-4-il)propan-1-ol como inhibidor de CYP17 para el tratamiento de enfermedades dependientes de andrógenos como el cáncer de próstata
|
WO2012082746A2
(en)
|
2010-12-13 |
2012-06-21 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitor compounds
|
CN103649028B
(zh)
|
2011-02-25 |
2015-10-14 |
美国政府健康及人类服务部 |
抑制FtsZ蛋白的克利斯汀类似物
|
EP2683410A2
(en)
|
2011-03-08 |
2014-01-15 |
Access Pharmaceuticals, Inc. |
Targeted nanocarrier systems for delivery of actives across biological membranes
|
AU2012273166A1
(en)
|
2011-06-19 |
2014-01-23 |
Viamet Pharmaceuticals (NC), Inc. |
Metalloenzyme inhibitor compounds
|
BR122020013521B1
(pt)
|
2011-06-19 |
2021-05-25 |
Viamet Pharmaceuticals (NC), Inc |
compostos inibidores de metaloenzima
|
US8883797B2
(en)
|
2011-06-23 |
2014-11-11 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitor compounds
|
WO2013019169A1
(en)
|
2011-08-01 |
2013-02-07 |
Institute For Oneworld Health |
Phosphate prodrugs
|
JP2014531425A
(ja)
|
2011-09-02 |
2014-11-27 |
ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク |
肥満の代謝異常を治療するためのCaMKII、IP3R、カルシニューリン、p38、およびMK2/3阻害剤
|
BR112014013963B1
(pt)
|
2011-12-11 |
2021-06-22 |
Nqp 1598, Ltd |
Compostos inibidores de metaloenzimas, composições compreendendo os ditos compostos, uso terapêutico dos mesmos e métodos para inibir a atividade de metaloenzimas e para tratar ou prevenir o crescimento de fungos em plantas
|
IN2014DN06792A
(es)
|
2012-01-20 |
2015-05-22 |
Viamet Pharmaceuticals Inc |
|
JP6231548B2
(ja)
|
2012-03-23 |
2017-11-15 |
マテオン セラピューティクス, インコーポレイテッド |
カテプシンの阻害のための組成物および方法
|
WO2013173506A2
(en)
|
2012-05-16 |
2013-11-21 |
Rigel Pharmaceuticals, Inc. |
Method of treating muscular degradation
|
WO2014012653A1
(en)
*
|
2012-07-16 |
2014-01-23 |
Grünenthal GmbH |
Pharmaceutical patch for transdermal administration of tapentadol
|
WO2014013014A1
(en)
|
2012-07-18 |
2014-01-23 |
Fundació Privada Centre De Regulació Genòmica (Crg) |
Jak inhibitors for activation of epidermal stem cell populations
|
EP2948150A1
(en)
|
2013-01-25 |
2015-12-02 |
Rigel Pharmaceuticals, Inc. |
Compounds and methods for treating inflammatory bowel diseases
|
KR20150129847A
(ko)
|
2013-03-15 |
2015-11-20 |
더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 |
융합 단백질 및 이들의 방법
|
EP3119415A4
(en)
|
2014-03-07 |
2017-11-29 |
The Arizona Board of Regents on behalf of the University of Arizona |
Non-narcotic crmp2 peptides targeting sodium channels for chronic pain
|
WO2015143184A1
(en)
|
2014-03-19 |
2015-09-24 |
Viamet Pharmaceuticals, Inc. |
Antifungal compound process
|
EP3925979A3
(en)
|
2014-12-23 |
2022-03-23 |
The Trustees of Columbia University in the City of New York |
Fgfr-tacc fusion proteins and methods thereof
|
BR112017018823A2
(pt)
|
2015-03-19 |
2018-04-24 |
Viamet Pharmaceuticals, Inc. |
compostos antifúngicos e processos para a fabricação
|
EP3719016A1
(en)
|
2015-08-04 |
2020-10-07 |
Rigel Pharmaceuticals, Inc. |
Benzazole compounds and methods for making and using the compounds
|
BR112018005198A2
(pt)
|
2015-09-18 |
2018-10-09 |
Vps-3, Inc. |
compostos antifúngicos e processos de manufatura
|
US10188750B1
(en)
|
2015-10-23 |
2019-01-29 |
University Of South Florida |
Self-replicating cell selective gene delivery compositions, methods, and uses thereof
|
CN108779094B
(zh)
|
2015-12-30 |
2021-11-16 |
Nqp 1598公司 |
金属酶抑制剂化合物
|
ES2940911T3
(es)
|
2016-06-27 |
2023-05-12 |
Rigel Pharmaceuticals Inc |
Compuestos de 2,4-diamino-pirimidina y su uso como inhibidores de IRAK4
|
WO2018002888A1
(en)
|
2016-06-29 |
2018-01-04 |
Halo Life Science, Llc |
Methods of making low odor choline salts of an organic compound
|
CN115531387A
(zh)
|
2016-10-26 |
2022-12-30 |
里格尔药品股份有限公司 |
用作irak抑制剂的吡唑酰胺化合物
|
CA3041587A1
(en)
|
2016-10-26 |
2018-05-17 |
Rigel Pharmaceuticals, Inc. |
Oxazole derivatives for use as irak inhibitors and method for their preparation
|
CA3055292A1
(en)
|
2016-12-29 |
2018-07-05 |
Selenity Therapeutics (Bermuda), Ltd. |
Metalloenzyme inhibitor compounds
|
EP3562306A4
(en)
|
2016-12-29 |
2020-06-24 |
Selenity Therapeutics (Bermuda), Ltd. |
METALLOENZYME INHIBITOR COMPOUNDS
|
EP3645525A1
(en)
|
2017-06-29 |
2020-05-06 |
Rigel Pharmaceuticals, Inc. |
Kinase inhibitors and methods for making and using
|
US20210292410A1
(en)
|
2017-12-07 |
2021-09-23 |
Morphosys Ag |
Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
|
JP2021523226A
(ja)
|
2018-05-03 |
2021-09-02 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
Rip1阻害剤化合物並びにそれを製造及び使用するための方法
|
ES2947446T3
(es)
|
2018-05-03 |
2023-08-09 |
Rigel Pharmaceuticals Inc |
Compuestos inhibidores de RIP1 y métodos para fabricar y usar los mismos
|
US20220000880A1
(en)
|
2018-11-01 |
2022-01-06 |
Rigel Pharmaceuticals, Inc. |
Method and composition embodiments for treating acute myeloid leukemia
|
WO2020243612A1
(en)
|
2019-05-29 |
2020-12-03 |
Rigel Pharmaceuticals, Inc. |
Method of preventing and treating thrombosis
|
MX2022001596A
(es)
|
2019-08-08 |
2022-03-11 |
Rigel Pharmaceuticals Inc |
Compuestos y metodos para tratar sindrome de liberacion de citocinas.
|
EP4013420B1
(en)
|
2019-08-14 |
2023-11-01 |
Rigel Pharmaceuticals, Inc. |
Method of blocking or ameliorating cytokine release syndrome
|
BR112022003564A2
(pt)
|
2019-08-30 |
2022-05-17 |
Rigel Pharmaceuticals Inc |
Composto, composição, composição seca por pulverização, método de preparação de uma composição seca por pulverização e método
|
CR20220075A
(es)
|
2019-09-06 |
2022-07-14 |
Rigel Pharmaceuticals Inc |
Compuestos inhibidores de rip1 y métodos para prepararlos y usarlos
|
AU2020341681B2
(en)
|
2019-09-06 |
2024-02-15 |
Rigel Pharmaceuticals, Inc. |
RIP1 inhibitory compounds and methods for making and using the same
|
US11578078B2
(en)
|
2019-11-07 |
2023-02-14 |
Rigel Pharmaceuticals, Inc. |
Heterocyclic RIP1 inhibitory compounds
|
WO2022187303A1
(en)
|
2021-03-03 |
2022-09-09 |
Rigel Pharmaceuticals, Inc. |
A method for treating a disease or condition using a pyrazole compound or formulation thereof
|
TW202300490A
(zh)
|
2021-03-11 |
2023-01-01 |
美商雷傑製藥公司 |
雜環rip1激酶抑制劑
|
US20230303555A1
(en)
|
2022-03-23 |
2023-09-28 |
Rigel Pharmaceuticals, Inc. |
Pyrimid-2-yl-pyrazole compounds as irak inhibitors
|
US20230312568A1
(en)
|
2022-03-31 |
2023-10-05 |
Rigel Pharmaceuticals, Inc. |
Tricyclic irak inhibitors
|